Treatment of Infantile Hemangiomas with Sirolimus in a Patient with PHACE Syndrome

• DOI: 10.1111/pde.12023
• Publication Date: 2013-01-15T07:28:40Z
• Authors: Samer Kaylani; Amy J. Theos; Joseph G. Pressey
• Keywords: Sirolimus; Pathogenesis; Infantile hemangioma

Infantile hemangiomas (IHs) are common benign tumors of childhood. IHs often regress satisfactorily without intervention, but a subset may lead to functional or cosmetic morbidity necessitating therapy. PHACE syndrome is characterized by variety neurocutaneous and vascular anomalies that typically include segmental hemangiomas. We present an infant with IH failed conventional first-line therapies. Treatment sirolimus provided benefit regression the cutaneous IH. As inhibitor mammalian target rapamycin (mTOR) pathway, effective use shed light on emerging role mTOR signaling in development pathogenesis IHs.